Gilbert Smolyak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gilbert Smolyak has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alayna E. Loiselle
University of Rochester Medical Center
1 shared publication - Andrew J. Rodenhouse
Department of Orthopaedics and Physical Performance, University of Rochester Medical Center, Rochester, NY, USA
1 shared publication - Anne E. C. Nichols
University of Rochester Medical Center
1 shared publication Bowen Qiu
Department of Orthopaedics and Rehabilitation, University of Rochester Medical Center, Rochester, NY
1 shared publicationConstantinos Ketonis
Department of Orthopaedics and Rehabilitation, University of Rochester Medical Center, Rochester, NY; Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY
1 shared publication- Constantinos Ketonis
University of Rochester Medical Center, Department of Orthopaedic Surgery, 10 Miracle Mile Drive, Rochester, NY, 14623, USA
1 shared publication
Latest Publications
- Open Access
- 3 April 2025
- Published by Wiley in FASEB BioAdvances
- Vol. 7 (5) , e70008
Ogerin induced activation of Gpr68 alters tendon healing
Satisfactory outcomes after acute tendon injuries are hampered by a fibrotic healing response. As such, modulation of extracellular matrix deposition and remodeling represents an important intervention point to improve healing. During fibrosis, matrix is deposited and remodeled by activated fibroblasts and/or myofibroblasts. Recent work has demonstrated that Ogerin, a positive allosteric modulator of the orphan proton‐sensing GPCR, GPR68, can modulate fibroblast ↔ myofibroblast dynamics in multiple fibroblast populations, including blunting myofibroblast differentiation and facilitating reversion of mature myofibroblasts to a basal fibroblast state in vitro. In the present study, we tested the ability of Ogerin to modulate tendon fibroblast ↔ myofibroblast behavior in vitro and in vivo. Consistent with prior work, Ogerin can both blunt TGF‐β induced tenocyte → myofibroblast differentiation and partially revert mature myofibroblasts to a basal tenocyte state. However, Ogerin treatment from days 8–12 after tendon repair surgery did not inhibit myofibroblast differentiation, and Ogerin treatment from post‐operative days 24–28 did not induce myofibroblast reversion. Moreover, while we expected Ogerin treatment from days 8–12 to impair healing due to blunted extracellular matrix formation, Ogerin treatment improved tendon mechanical properties and altered cell transcriptional profiles and communication patterns in a way that suggests accelerated remodeling and resolution of the repair response, identifying Ogerin as a novel therapeutic approach to improve the tendon healing process.
- 3 April 2025
- Published by Wiley in FASEB BioAdvances
- Vol. 7 (5) , e70008
Open AccessOgerin induced activation of Gpr68 alters tendon healing
Satisfactory outcomes after acute tendon injuries are hampered by a fibrotic healing response. As such, modulation of extracellular matrix deposition and remodeling represents an important intervention point to improve healing. During fibrosis, matrix is deposited and remodeled by activated fibroblasts and/or myofibroblasts. Recent work has demonstrated that Ogerin, a positive allosteric modulator of the orphan proton‐sensing GPCR, GPR68, can modulate fibroblast ↔ myofibroblast dynamics in multiple fibroblast populations, including blunting myofibroblast differentiation and facilitating reversion of mature myofibroblasts to a basal fibroblast state in vitro. In the present study, we tested the ability of Ogerin to modulate tendon fibroblast ↔ myofibroblast behavior in vitro and in vivo. Consistent with prior work, Ogerin can both blunt TGF‐β induced tenocyte → myofibroblast differentiation and partially revert mature myofibroblasts to a basal tenocyte state. However, Ogerin treatment from days 8–12 after tendon repair surgery did not inhibit myofibroblast differentiation, and Ogerin treatment from post‐operative days 24–28 did not induce myofibroblast reversion. Moreover, while we expected Ogerin treatment from days 8–12 to impair healing due to blunted extracellular matrix formation, Ogerin treatment improved tendon mechanical properties and altered cell transcriptional profiles and communication patterns in a way that suggests accelerated remodeling and resolution of the repair response, identifying Ogerin as a novel therapeutic approach to improve the tendon healing process.
- 18 November 2024
- Published by Wolters Kluwer Health in International Anesthesiology Clinics
- Vol. 63 (1) , 1-13
Establishing and Managing an Ambulatory Surgery Center: Planning, Launching, Operating, and Sustaining Success
- 18 November 2024
- Published by Wolters Kluwer Health in International Anesthesiology Clinics
- Vol. 63 (1) , 1-13
Establishing and Managing an Ambulatory Surgery Center: Planning, Launching, Operating, and Sustaining Success
- 15 August 2023
- Published by Elsevier in The Journal of Hand Surgery
- Vol. 48 (11) , 1098-1104
Association of Patient-Reported Outcomes Measurement Information System Measures With Injection and Surgical Treatment Response in Patients With De Quervain Tenosynovitis
- 15 August 2023
- Published by Elsevier in The Journal of Hand Surgery
- Vol. 48 (11) , 1098-1104
Association of Patient-Reported Outcomes Measurement Information System Measures With Injection and Surgical Treatment Response in Patients With De Quervain Tenosynovitis